Part D marketing fails to meet CMS guidelines 85% of time
Executive Summary
HHS' Office of Inspector General says that most marketing material for Medicare Part D prescription drug plans fails to meet at least one element of CMS guidelines, ranging from details about PDP benefits and rules to requirements for footnote font size. "It's unconscionable that CMS has let the insurance industry's materials - including essential items like pharmacy directories and summaries of benefits - fail to properly inform seniors 85 percent of the time," Senate Finance Committee Chairman Max Baucus, D-Mont., said. "CMS says it's making changes to correct these problems, and you'd better believe the Finance Committee will move to make sure seniors get better service one way or the other.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.